<?xml version="1.0"?>
<Articles JournalTitle="Basic &amp; Clinical Cancer Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Basic &amp; Clinical Cancer Research</JournalTitle>
      <Issn>2228-6527</Issn>
      <Volume>14</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="epublish">
        <Year>2023</Year>
        <Month>10</Month>
        <Day>21</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Computer-aided peptide-based drug design for inositol-requiring enzyme 1</title>
    <FirstPage>185</FirstPage>
    <LastPage>197</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Alireza</FirstName>
        <LastName>Ghanbari</LastName>
        <affiliation locale="en_US">NIGEB</affiliation>
      </Author>
      <Author>
        <FirstName>Amir</FirstName>
        <LastName>Norouzy</LastName>
        <affiliation locale="en_US">NIGEB</affiliation>
      </Author>
      <Author>
        <FirstName>Negar</FirstName>
        <LastName>Balmeh</LastName>
        <affiliation locale="en_US">NIGEB</affiliation>
      </Author>
      <Author>
        <FirstName>Najaf</FirstName>
        <LastName>Allahyari Fard</LastName>
        <affiliation locale="en_US">NIGEB</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammad</FirstName>
        <LastName>Moosavi</LastName>
        <affiliation locale="en_US">NIGEB</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>09</Month>
        <Day>24</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2023</Year>
        <Month>10</Month>
        <Day>01</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Inositol-requiring enzyme 1 (IRE1), an endoplasmic reticulum (ER) transmembrane
protein with both kinase and endoribonuclease activities, plays an essential role during
ER stress and its subsequent unfolded protein response (UPR). Recent evidence shows
IRE1 signaling contributes to tumorigenesis and cancer progression, pointing to the
therapeutic importance of this conserved arm of the UPR. Here, we employed different
computational tools to design and predict short peptides with the capability of disrupting IRE1 dimerization/oligomerization, as a strategy for inhibiting its Kinase and
RNase activities. A mutation-based peptide library was constructed using mCSM-PPI2
and OSPREY 3.0. The molecular interaction analyses between the designed peptides
and IRE1 protein were conducted using the HADDOCK 2.2 online server, followed
with molecular dynamics analysis by the GROMACS 2020 package. We then selected
short peptide candidates that exhibited high affinity and best predicted physicochemical properties in complex with IRE1. Finally, online servers, such as ToxinPred and
AllerTop, were used to identify the best peptide candidates that showed no significant
allergenic or cytotoxic properties. These rational designed peptides with the capability
of binding to IRE1 oligomerization domain can be considered as potential drug candidates for disrupting IRE1 activity in cancer and related diseases, pending for further
validation by in silico and experimental studies.</abstract>
    <web_url>https://bccr.tums.ac.ir/index.php/bccrj/article/view/495</web_url>
  </Article>
</Articles>
